MarginsXMarginsX
Home › Markets › Health Care › BIAF

bioAffinity Technologies Inc. (BIAF)

BIAF trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.00
-9.09% on the day
Market cap
$3.6M
Nano cap
Revenue · 2025
$6.2M
-34.2% on 2024
Net income · 2025
-$14.9M
-242.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1712762/000149315226010143/0001493152-26-010143-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBIAF on Nasdaq
SectorHealth Care
IndustryBiotechnology: Commercial Physical & Biological Resarch
CountryUnited States
IPO year2022
SEC CIK0001712762
SEC industry codeServices-Commercial Physical & Biological Research
Incorporated inDE

Financials · 2025

LineValue
Revenue$6.2M
Net income-$14.9M
Operating income-$10.6M
Net margin-242.0%
Operating margin-171.6%
Revenue growth-34.2%
Cash$6.4M
Total assets$11.0M
P/E (computed)Net income was not positive
P/S (computed)0.6×

Warning signs

Cash runway
2.4 months
$2.6M cash at September 30, 2026
Share count, 1 year
+506.8%
2025-11-11 to 2026-11-05 · +8519.0% over 3 years
Going-concern doubt
Yes
10-Q filed November 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Based on the Company's current expected level of operating expenditures and the cash and cash equivalents on hand at September 30, 2026, management concludes that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance of the accompanying unaudited condensed consolidated financial statements."
10-Q 2026-11-06
Cash and burn$2.6M cash; operating cash flow -$3.2M a quarter.Report 2026-09-30
Shares outstanding1,820,006 (2026-11-05); 4,498,709 a year earlier; 9,502,243 three years earlier. 1y figure adjusted for splits (1-for-15 overall); 3y figure adjusted for splits (1-for-450 overall).Cover page 2026-11-05
Reverse splits, 3 years2; latest 1-for-15 on 2026-08-24Source 2026-08-24
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the marketLatest 2026-11-03
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-07-31
AuditorWithumSmith+Brown, PC, New York, New York, United StatesPCAOB Form AP 2026-03-19
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.1M-$5.3M-$3.9M$2.6M$305K$5.5M10-Q 2026-11-06
Q2 2026
2026-06-30
$1.5M-$3.4M-$3.2M$2.4M$23K$5.9M10-Q 2026-08-07
Q1 2026
2026-03-31
$1.4M-$3.6M-$3.2M$3.1M$61K$5.7M10-Q 2026-05-11
Q4 2025
2025-12-31
$1.6M-$3.1M-$2.6M$6.4M$105K$6.2M10-K 2026-03-16
Q3 2025
2025-09-30
$1.4M-$5.1M-$2.5M$7.7M$396K$6.8M10-Q 2026-11-06
Q2 2025
2025-06-30
$1.3M-$4.1M-$2.6M$803K$33K$7.7M10-Q 2026-08-07
Q1 2025
2025-03-31
$1.9M-$2.7M-$1.6M$445K$105K$8.8M10-Q 2026-05-11
Q4 2024
2024-12-31
$2.2M-$3.0M-$1.7M$1.1M$172K$9.4M10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-03
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-06
Latest proxyDEF 14A2026-10-23

Source: SEC EDGAR submissions feed, 401 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-19.0%
1 month-39.3%
3 months-61.7%
Year to date-87.6%
1 year-92.2%
From 52-week high-96.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
BIAFWbioAffinity Technologies Inc. Warrant$0.2200

Peers in Biotechnology: Commercial Physical & Biological Resarch

TickerCompanyPriceDayMarket cap
ISPCiSpecimen Inc.$0.6049-8.17%$3.3M
ONMDOneMedNet Corp$4.86-8.99%$29.2M
MXCTMaxCyte Inc.$1.18-0.84%$121.8M
NRCNRC Health$26.33-0.87%$558.8M
OABIOmniAb Inc.$4.89-0.41%$713.3M
ABSIAbsci Corporation$7.47-11.54%$1.3B
ICLRICON plc$191.40-1.67%$14.7B
CRLCharles River Laboratories International Inc.$335.52-0.72%$16.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier